Last reviewed · How we verify
NCT04758793: UNIVERSE
Muscles in Liver Diseases
NA trial testing blood samples in Patients Having a Scheduled Abdominal Surgery Procedure in 260 participants. Not yet recruiting.
31 May 2026
Quick facts
| Lead sponsor | Assistance Publique - Hôpitaux de Paris |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 260 |
| Start date | 15 February 2021 |
| Primary completion | 31 May 2026 |
| Estimated completion | 31 May 2026 |
Drugs / interventions tested
- blood samples — full drug profile →
- biopsy of abdominal paroie
Conditions studied
- Patients Having a Scheduled Abdominal Surgery Procedure — all drugs for Patients Having a Scheduled Abdominal Surgery Procedure →
Sponsor
Assistance Publique - Hôpitaux de Paris — full company profile →
Who can join
18 and older, any sex, with Patients Having a Scheduled Abdominal Surgery Procedure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cirrhosis is the 11th leading cause of death in the world. The progression to cirrhosis occurs as a result of chronic hepatic injury, related to excessive alcohol consumption, non-alcoholic steatohepatitis, chronic viral infection. Cirrhosis is accompanied by symptoms that profoundly affect the quality of life of patients. Sarcopenia, or decrease in muscle capacity through loss of muscle mass, is associated with liver disease. Patients with liver disease and sarcopenia have increased morbidity, and higher pre- and post-liver transplant mortality than patients without sarcopenia. The mechanism responsible for the development of sarcopenia in liver disease remains largely misunderstood, as do the mechanisms by which sarcopenia appears to promote complications of liver disease. This study, carried out on a prospective cohort of patients with liver disease, aims at understanding the pathophysiological mechanisms involved in sarcopenia and its consequences.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Unveiling the Potential of Extracellular Vesicles as Biomarkers and Therapeutic Nanotools for Gastrointestinal Diseases.
Arrè V, Mastrogiacomo R, Balestra F, Serino G, et al · · 2024 · cited 8× · PMID 38675228 · DOI 10.3390/pharmaceutics16040567 -
Extracellular Vesicles: Orchestrators of Intrahepatic and Systemic Crosstalk in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Lei Y, Liu M, Tao X. · · 2026 · PMID 41599223 · DOI 10.3390/pharmaceutics18010116
Verify or expand the search:
- PubMed search for NCT04758793
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of blood samples
Trials testing the same drug.
- NCT07070102 — Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children · not yet recruiting
- NCT06252415 — Evaluation of Rapid First-line Genome Sequencing for Prenatal Diagnosis of Congenital Malformations in Comparison With C · completed
- NCT05472883 — Identification of Human Biomarkers Predictive of Diabetes Remission in Type 2 Diabetes Patient (BARIAKINES) · NA · recruiting
- NCT05472519 — Immunopathology of Loeys-Dietz Syndrome · NA · completed
- NCT07069296 — Impact of Gestational Diabetes on Childhood Obesity · NA · completed
Other Assistance Publique - Hôpitaux de Paris trials
Trials by the same sponsor.
- NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
- NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
- NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
- NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
- NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04758793 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
- Last refreshed: 17 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04758793.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing